Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023

Area of Science:

• Pharmacology and Drug Development
• Biotechnology and Biologics
• Regulatory Science

Background:

• The U.S. Food and Drug Administration (FDA) saw an increase in total drug approvals in 2023 compared to 2022.
• Biologics, including monoclonal antibodies (mAbs), consistently showed high approval rates, even during periods of lower overall authorizations.
• Cancer and autoimmune conditions were the primary targets for mAb approvals.

Purpose of the Study:

• To review significant drug approvals by the FDA in 2023, focusing on biologics like mAbs, enzymes, and proteins.
• To analyze the mechanisms of action, clinical outcomes, and comparative advantages of newly approved drugs.
• To examine the influence of expedited programs and Orphan Drug Designation on FDA approvals and the agency's decision-making independence.

Main Methods:

• Narrative review of FDA drug approval data from 2023.
• Analysis of drug classes, targeted diseases, and utilization of expedited pathways.
• Examination of biologics, including monoclonal antibodies, enzymes, and proteins, detailing their therapeutic applications.

Main Results:

• Total FDA drug approvals increased in 2023, with biologics playing a significant role.
• Over half of 2023 approvals involved expedited programs, reflecting increased disease incidence.
• More than 50% of approved biologics received Orphan Drug Designation.
• Monoclonal antibodies predominantly targeted cancer, followed by autoimmune diseases.

Conclusions:

• The FDA's 2023 approval landscape was characterized by a rise in overall approvals, a strong presence of biologics, and significant use of expedited pathways.
• Expedited programs and Orphan Drug Designation are crucial for bringing novel therapies, particularly for rare diseases and cancer, to market.
• Understanding external influences on FDA decisions is vital for maintaining regulatory integrity and ensuring timely access to innovative medicines.